- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01694394
Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor (ASSERT-II)
Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patient With Cardiovascular Risk Factors (ASSERT-II)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Title of Study Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients with Cardiovascular Risk Factors (ASSERT-II) Short Title ASSERT-II Study Sponsor Population Health Research Institute (Grant in Aid from St. Jude Medical, Inc.) Principal Investigators Dr. J. Healey, Dr. S. Connolly, Dr. M. Alings Central Coordinating Centre Population Health Research Institute Recruitment and Participating Clinical Sites 250 patients from approximately 30 Sites Phase/Regulatory Status Phase IV - Cohort Study Hypothesis Among elderly patients with cardiovascular risk factors and a left atrial diameter ≥ 4.4 cm, but without prior clinical AF, an implanted continuous ECG monitor (St. Jude Medical Confirm® Implantable Cardiac Monitor) will detect subclinical AF (≥ 5 minutes in duration) in 12% or more of patients during an average follow-up of 12 months.
Study Objectives
Primary Objectives:
1. To determine the rate of detection of sub-clinical atrial AF (≥ 5 minutes) within an average of 12 months following implant of the St. Jude Medical Confirm® Implantable Cardiac Monitor in patients with known cardiovascular risk factors and left atrial enlargement, but without prior AF.
Secondary Objectives
- To determine if the incidence of sub-clinical AF is higher among patients whose left atrial volume is above the median value observed in this study.
- To determine the relationship between left atrial volume (continuous variable) and the risk of sub-clinical AF.
- To evaluate other potential predictors of sub-acute AF in this population including: baseline troponin-T, baseline NT-pro-BNP as well as clinical and other echocardiographic parameters.
- To develop a preliminary economic analysis to evaluate the potential cost-effectiveness of screening this patient population with an Implantable Cardiac Monitor as a means of preventing stroke.
Study Design Cohort study to determine the prevalence of sub-clinical AF in an elderly population with common cardiovascular risk factors, such as hypertension and diabetes. Patients with echocardiographic evidence of atrial enlargement will be enrolled and have the St. Jude Medical Confirm® Implantable Cardiac Monitor (Confirm® ICM) subcutaneously implanted. To reduce costs, in most cases the implant will be done in conjunction with other planned surgery or heart catheterization.
PHRI: CONFIDENTIAL Final Version 2.0:2012-06-18 Page 4 of 24 Participants/Study Duration Total of 250 participants will be enrolled over 16 months. The last patient enrolled will have 9 months of follow-up, for a total study duration of approximately 25 months. Clinic visits will occur at enrolment and months 3, 6 and 9. A final visit will take place at 18 months of follow-up, or after the last patient enrolled has been followed for 9 months (whichever comes first).
Study Population Patients with known cardiovascular risk factors and left atrial enlargement, with no prior documented AF.
Intervention St. Jude Medical Confirm® Implantable Cardiac Monitor (Confirm® ICM) Enrollment and Follow-up Eligible and consenting patients will be enrolled and have the Confirm® ICM implanted. The implant may take place in conjunction with pre-planned non-cardiac surgery, heart catheterization, or as a stand-alone procedure. Follow-up visits will occur at month 3, 6 and 9. A final visit will take place at 18 months of follow-up, or after the last patient enrolled has been followed for 9 months (whichever comes first).
Assessment of Outcome Events An independent central adjudication committee comprised of arrhythmia experts will evaluate device-detected AF episodes.
Statistical Methodology Determine the incidence of sub-clinical atrial AF (≥ 5 minutes) using the Confirm® ICM.
Date of Protocol June 18, 2012
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- University of Calgary
-
-
Manitoba
-
Winnepeg, Manitoba, Canada, R2H 2A6
- St. Boniface Hospital
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 3A7
- Queen Elizabeth-II Heather Sciences Center
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences - Electrophysiology Clinic
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences - Interventional Cardiology
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences - Perioperative Ischemia Research Group
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Center University Hospital
-
Newmarket, Ontario, Canada, L3Y 2P9
- Southlake Regional HealthCare
-
Ottawa, Ontario, Canada, 613-761-5208
- University of Ottawa Heart Institute
-
Sudbury, Ontario, Canada, P3E 5J1
- Health Sciences North
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H9S 1H4
- McGill University Health Centre
-
Sainte-Foy, Quebec, Canada, G1V 4G5
- Institut universitaire de cardiologie et de pneumologie de Québec (Hôpital Laval)
-
-
-
-
-
Amsterdam, Netherlands, 1100 DD
- Academisch Medisch Centrum (AMC) Amsterdam
-
Breda, Netherlands, 4818 CK
- Amphia Hospital
-
Drachten, Netherlands, 9202 DA
- Nij Smellinge
-
Gouda, Netherlands, 2803 HH
- Groene Hart Ziekenhuis Gouda
-
Leiden, Netherlands, 2334 CK
- Diakonessenhuis Leiden
-
Rotterdam, Netherlands, 3083 AN
- Ikazia Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria
Patients will be eligible for inclusion if they meet both of the following:
Age ≥ 65, plus:
- CHA2DS2-VASc score ≥ 2 Or
- Obstructive sleep apnea (documented by polysomnography, ambulatory oximetry, positive Berlin Questionnaire or requiring the use of CPAP/BiPAP) Or
- BMI > 30
Echocardiographic or biochemical evidence of increased risk of AF:
- Left atrial enlargement on a clinical echocardiography at any time prior to enrollment ( defined as LA volume ≥ 58 ml or LA diameter of ≥ 4.4 cm) Or
- Serum NT-ProBNP ≥ 290 pg/mL Exclusion Criteria
1. Previously documented history of atrial fibrillation or atrial flutter 2. Current chronic treatment with oral anticoagulation (i.e. those on peri-operative prophylaxis would be eligible) 3. Patient with implanted pacemaker or defibrillator with an atrial lead 4. Definitive plan for cardiac surgery in the next 6 months (patients who are having coronary angiography with a possibility of cardiac surgery are still eligible)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cohort
Single arm cohort will receive a St. Jude Medical Implantable Cardiac Monitor (Confirm ICM model 2102) for continuous monitoring over the study follow-up period to determine incidence of sub-clinical atrial fibrillation.
|
Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First atrial fibrillation episode at least 5 minutes in duration
Time Frame: over maximum follow-up of 18 months
|
incidence of atrial fibrillation detected by continuous monitoring by an implantable cardiac monitor
|
over maximum follow-up of 18 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jeff Healey, M.D., Population Health Research Institute
- Principal Investigator: Stuart Connolly, M.D., Population Health Research Institute
- Principal Investigator: Marco Alings, M.D., Working Group Cardiovascular Research Netherlands
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASSERT-II
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Maastricht UniversityRadboud University Medical Center; Maastricht University Medical CenterRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Atrial Fibrillation ParoxysmalNetherlands
Clinical Trials on Implantable Cardiac Monitor (Confirm ICM model 2102)
-
Oxford University Hospitals NHS TrustRecruiting
-
University Hospital Inselspital, BerneAbbott; University Hospital, Zürich; Bangerter-Rhyner StiftungRecruitingAtrial Fibrillation | MINOCASwitzerland
-
Medtronic Corporate Technologies and New VenturesCompletedEnd Stage Renal DiseaseUnited States, India
-
University of RochesterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPathologic Processes | Heart Diseases | Cardiovascular Diseases | Atrial Fibrillation | Arrhythmias, CardiacUnited States
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrial FibrillationUnited States, Slovenia, Germany, Netherlands, Italy, Spain, Austria
-
Erasmus Medical CenterMedtronicCompletedChronic Total Occlusion of Coronary ArteryNetherlands
-
Hospital Clinico Universitario de SantiagoHospital Universitario Virgen de la Arrixaca; University of Salamanca; Hospital...RecruitingHeart Failure | Atrial FibrillationSpain
-
LMU KlinikumMedtronic Bakken Research Center; Deutsches Zentrum für Herz-Kreislauf-Forschung...CompletedMyocardial Infarction | Autonomic Nervous System DiseasesGermany, Austria
-
Hospital Universitari Vall d'Hebron Research InstituteRecruitingParoxysmal Atrial Fibrillation | Cryptogenic StrokeSpain